Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 838
Filter
2.
Chinese Journal of Hematology ; (12): 380-387, 2023.
Article in Chinese | WPRIM | ID: wpr-984633

ABSTRACT

Objective: To understand the current status of diagnosis and treatment of chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL) among hematologists, oncologists, and lymphoma physicians from hospitals of different levels in China. Methods: This multicenter questionnaire survey was conducted from March 2021 to July 2021 and included 1,000 eligible physicians. A combination of face-to-face interviews and online questionnaire surveys was used. A standardized questionnaire regarding the composition of patients treated for CLL/SLL, disease diagnosis and prognosis evaluation, concomitant diseases, organ function evaluation, treatment selection, and Bruton tyrosine kinase (BTK) inhibitor was used. Results: ①The interviewed physicians stated that the proportion of male patients treated for CLL/SLL is higher than that of females, and the age is mainly concentrated in 61-70 years old. ②Most of the interviewed physicians conducted tests, such as bone marrow biopsies and immunohistochemistry, for patient diagnosis, in addition to the blood test. ③Only 13.7% of the interviewed physicians fully grasped the initial treatment indications recommended by the existing guidelines. ④In terms of cognition of high-risk prognostic factors, physicians' knowledge of unmutated immunoglobulin heavy-chain variable and 11q- is far inferior to that of TP53 mutation and complex karyotype, which are two high-risk prognostic factors, and only 17.1% of the interviewed physicians fully mastered CLL International Prognostic Index scoring system. ⑤Among the first-line treatment strategy, BTK inhibitors are used for different types of patients, and physicians have formed a certain understanding that BTK inhibitors should be preferentially used in patients with high-risk factors and elderly patients, but the actual use of BTK inhibitors in different types of patients is not high (31.6%-46.0%). ⑥BTK inhibitors at a reduced dose in actual clinical treatment were used by 69.0% of the physicians, and 66.8% of the physicians had interrupted the BTK inhibitor for >12 days in actual clinical treatment. The use of BTK inhibitors is reduced or interrupted mainly because of adverse reactions, such as atrial fibrillation, severe bone marrow suppression, hemorrhage, and pulmonary infection, as well as patients' payment capacity and effective disease progression control. ⑦Some differences were found in the perceptions and behaviors of hematologists and oncologists regarding the prognostic assessment of CLL/SLL, the choice of treatment options, the clinical use of BTK inhibitors, etc. Conclusion: At present, a gap remains between the diagnosis and treatment of CLL/SLL among Chinese physicians compared with the recommendations in the guidelines regarding the diagnostic criteria, treatment indications, prognosis assessment, accompanying disease assessment, treatment strategy selection, and rational BTK inhibitor use, especially the proportion of dose reduction or BTK inhibitor discontinuation due to high adverse events.


Subject(s)
Female , Humans , Male , Aged , Middle Aged , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Prognosis , Lymphoma, B-Cell , Immunohistochemistry , Immunoglobulin Heavy Chains/therapeutic use
3.
Chinese Journal of Contemporary Pediatrics ; (12): 51-59, 2023.
Article in Chinese | WPRIM | ID: wpr-971039

ABSTRACT

OBJECTIVES@#To study the efficacy and safety of rituximab combined with chemotherapy in the treatment of children and adolescents with mature B-cell non-Hodgkin's lymphoma (B-NHL) through a Meta analysis.@*METHODS@#The databases including PubMed, Embase, the Cochrane Library, ClinicalTrials.gov, Web of Science, China National Knowledge Infrastructure, Wanfang Data, and Weipu were searched to obtain 10 articles on rituximab in the treatment of mature B-NHL in children and adolescents published up to June 2022, with 886 children in total. With 3-year event-free survival (EFS) rate, 3-year overall survival (OS) rate, complete remission rate, mortality rate, and incidence rate of adverse reactions as outcome measures, RevMan 5.4 software was used for Meta analysis, subgroup analysis, sensitivity analysis, and publication bias analysis.@*RESULTS@#The rituximab+chemotherapy group showed significant increases in the 3-year EFS rate (HR=0.38, 95%CI: 0.25-0.59, P<0.001), 3-year OS rate (HR=0.29, 95%CI: 0.14-0.61, P=0.001), and complete remission rate (OR=3.72, 95%CI: 1.89-7.33, P<0.001) as well as a significant reduction in the mortality rate (OR=0.31, 95%CI: 0.17-0.57, P<0.001), as compared with the chemotherapy group without rituximab. There was no significant difference in the incidence rate of adverse reactions between the two groups (OR=1.28, 95%CI: 0.85-1.92, P=0.24).@*CONCLUSIONS@#The addition of rituximab to the treatment regimen for children and adolescents with mature B-cell non-Hodgkin's lymphoma can bring significant survival benefits without increasing the incidence of adverse reactions.


Subject(s)
Child , Adolescent , Humans , Rituximab/adverse effects , Lymphoma, B-Cell/drug therapy , Progression-Free Survival , Remission Induction , China , Antineoplastic Combined Chemotherapy Protocols/therapeutic use
4.
Rev. cir. traumatol. buco-maxilo-fac ; 22(2): 53-58, abr.-jun. 2022. ilus
Article in Portuguese | LILACS, BBO | ID: biblio-1399546

ABSTRACT

Introdução: O linfoma de Burkitt é um linfoma altamente agressivo do tipo não-hodgkin originado a partir de mutação nos linfócitos B. Clinicamente demonstra características de malignidade como evolução rápida, destruição das corticais ósseas e mobilidade dentária, além de aumento de volume facial adjacente aos ossos maxilares. Esse tumor é de difícil diagnóstico devido às características clínicas inespecíficas, o que pode muitas vezes levar a um diagnóstico e tratamento tardio, piorando o prognóstico e a taxa de sobrevida do paciente. Relato de Caso: O caso clínico se trata de uma paciente, sexo feminino, 21 anos de idade, com história de aumento de volume em hemiface esquerda de evolução repentina, associada a dor, febre e relato de exodontia recente. A história clínica e os achados clínicos inespecíficos simularam uma infecção odontogênica, a qual atrasou o diagnóstico e o tratamento correto. Após exames imaginológicos específicos, exploração cirúrgica e exame histopatológico foi possível chegar a um diagnóstico definitivo de linfoma de Burkitt e manejo adequado dessa patologia. Conclusão: É de extrema importância o papel do cirurgião-dentista na detecção precoce dessa patologia com envolvimento dos maxilares, uma vez que a remissão e/ou a cura depende da extensão da doença, do seu comportamento biológico e do momento do diagnóstico... (AU)


Introduction: Burkitt's lymphoma is a highly aggressive non-Hodgkin type lymphoma originated from a mutation in B lymphocytes. It clinically demonstrates malignant characteristics such as rapid evolution, destruction of bone corticals and tooth mobility, in addition to increased facial volume adjacent to the maxillary bones. This tumor is difficult to diagnose due to its nonspecific clinical characteristics, which can often lead to a late diagnosis and treatment, worsening the patient's prognosis and survival rate. Case Report: The clinical case is a female patient, 21 years old, with a history of swelling in the left hemiface of sudden evolution, associated with pain, fever and a report of recent extraction. Clinical history and nonspecific clinical findings simulated an odontogenic infection, which delayed diagnosis and correct treatment. After specific imaging exams, surgical exploration and histopathological examination, it was possible to reach a definitive diagnosis of Burkitt's lymphoma and adequate management of this pathology. Conclusion: The role of dentists in the early detection of this pathology with involvement of the jaws is extremely important, since remission and/or cure depends on the extent of the disease, its biological behavior and the time of diagnosis... (AU)


Introducción: El linfoma de Burkitt es un linfoma de tipo no Hodgkin altamente agresivo originado por una mutación en los linfocitos B. Clínicamente demuestra características malignas como rápida evolución, destrucción de corticales óseas y movilidad dentaria, además de aumento de volumen facial adyacente a los huesos maxilares. Este tumor es de difícil diagnóstico debido a sus características clínicas inespecíficas, lo que muchas veces puede llevar a un diagnóstico y tratamiento tardíos, empeorando el pronóstico y la supervivencia del paciente. Caso Clínico: El caso clínico es una paciente femenina, de 21 años de edad, con antecedente de tumefacción en hemifacial izquierdo de evolución súbita, asociada a dolor, fiebre y reporte de extracción reciente. La historia clínica y los hallazgos clínicos inespecíficos simularon una infección odontogénica, lo que retrasó el diagnóstico y el tratamiento correcto. Luego de exámenes imagenológicos específicos, exploración quirúrgica y examen histopatológico, se logró llegar a un diagnóstico definitivo de linfoma de Burkitt y manejo adecuado de esta patología. Conclusión: El papel de los odontólogos en la detección temprana de esta patología con compromiso de los maxilares es de suma importancia, ya que la remisión y/o curación depende de la extensión de la enfermedad, su comportamiento biológico y el momento del diagnóstico... (AU)


Subject(s)
Humans , Female , Young Adult , Surgery, Oral , Mouth Neoplasms , Lymphoma, B-Cell , Burkitt Lymphoma , Postoperative Complications , Tooth Mobility , Diagnosis, Differential , Jaw
5.
Chinese Journal of Hematology ; (12): 388-392, 2022.
Article in Chinese | WPRIM | ID: wpr-929573

ABSTRACT

Objective: To improve the positivity rate and accuracy of MYD88 mutation detection in patients with Waldenström macroglobulinemia (WM) . Methods: MYD88 mutation status was retrospectively evaluated in 66 patients diagnosed with WM in Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from June 2017 to June 2021. The positivity rate and accuracy of the different methods and specimens for MYD88 mutation detection were analyzed. Results: MYD88 mutations were detected in 51 of 66 patients with WM, with an overall positivity rate of 77%. The positivity rate of the next-generation sequencing (NGS) or allele-specific polymerase chain reaction (AS-PCR) was significantly higher than that of the first-generation Sanger sequencing (84% vs 71% vs 46%, P<0.05) . For the different specimens, the positivity rate for the lymph nodes or bone marrow was significantly higher than that of peripheral blood (79% vs 84% vs 52%, P<0.05) . The positivity rate of the MYD88 mutation in the lymph nodes, bone marrow, and peripheral blood determined by NGS was 86%, 90%, and 67%, respectively. The positivity rate in the lymph nodes, bone marrow, and peripheral blood detected by AS-PCR was 78%, 81%, and 53%, respectively. Thirty-nine patients with WM underwent ≥ 2 MYD88 mutation detections. The final MYD88 mutational status for each patient was used as the standard to determine the accuracy of the different methods and in different specimens. The accuracy of MYD88 mutation detection in the lymph nodes (n=18) and bone marrow (n=13) by NGS was significantly higher than that in the peripheral blood (n=4) (100% vs 100% vs 75%, P<0.05) . There was no statistically significant difference in the accuracy of MYD88 mutation detection by AS-PCR in the lymph nodes (n=15) , bone marrow (n=11) , or peripheral blood (n=16) (93% vs 91% vs 88%, P>0.05) . Conclusions: In the detection of the MYD88 mutation in patients diagnosed with WM, NGS or AS-PCR is more sensitive than Sanger sequencing. Lymph nodes and bone marrow specimens are better than peripheral blood specimens.


Subject(s)
Humans , China , Lymphoma, B-Cell , Mutation , Myeloid Differentiation Factor 88/metabolism , Retrospective Studies , Waldenstrom Macroglobulinemia/genetics
6.
Chinese Journal of Hematology ; (12): 215-220, 2022.
Article in Chinese | WPRIM | ID: wpr-929560

ABSTRACT

Objective: This study aimed to determine the efficacy of dose-enhanced immunochemotherapy followed by autologous peripheral blood stem cell transplantation (ASCT) in young patients with newly diagnosed high-risk aggressive B-cell lymphoma. Methods: A retrospective study was conducted to examine the clinical and survival data of young patients with high-risk aggressive B-cell lymphoma who received dose-enhanced immunochemotherapy and ASCT as first-line treatment between January 2011 and December 2018 in Blood Diseases Hospital. Results: A total of 63 patients were included in the study. The median age range was 40 (14-63) years old. In terms of the induction therapy regimen, 52 cases received R-DA-EP (D) OCH, and the remaining 11 received R-HyperCVAD/R-MA. Sixteen (25.4% ) patients achieved partial response in the mid-term efficacy assessment, and ten of them were evaluated as complete response after transplantation. The median follow-up was 50 (8-112) months, and the 3-year progression-free survival (PFS) rate and overall survival (OS) rate were (83.9±4.7) % and (90.4±3.7) % , respectively. Univariate analysis demonstrated that age-adjusted international prognostic index ≥2 scores was a negative prognostic factor for OS (P=0.039) , and bone marrow involvement (BMI) was an adverse prognostic factor for OS (P<0.001) and PFS (P=0.001) . However, multivariate analysis confirmed that BMI was the only independent negative predictor of OS (P=0.016) and PFS (P=0.001) . Conclusions: The use of dose-enhanced immunochemotherapy in combination with ASCT as first-line therapy in the treatment of young, high-risk aggressive B-cell lymphoma results in good long-term outcomes, and BMI remains an adverse prognostic factor.


Subject(s)
Adult , Humans , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Disease-Free Survival , Hematopoietic Stem Cell Transplantation , Lymphoma, B-Cell , Peripheral Blood Stem Cell Transplantation , Prognosis , Retrospective Studies , Stem Cell Transplantation , Transplantation, Autologous
7.
Journal of Experimental Hematology ; (6): 965-969, 2022.
Article in Chinese | WPRIM | ID: wpr-939717

ABSTRACT

Zanubrutinib is a highly selective second-generation BTK inhibitor developed in China and first approved by the U.S. Food and Drug Administration (FDA) as a novel antineoplastic drug. In recent years, with the birth of molecularly targeted drugs, the treatment of B-cell lymphoma have entered the era of targeted therapy, and immunotherapy has been widely accepted. Especially in some relapsed and refractory lymphomas, zanubrutinib has shown deep and sustained remissions and a favorable safety, which lays a foundation for precision therapy. In this review the clinical application and new progress for zanubrutinib in B-cell lymphoma was summarized briefly.


Subject(s)
Humans , Lymphoma, B-Cell/drug therapy , Piperidines/therapeutic use , Protein Kinase Inhibitors/therapeutic use , Pyrazoles/therapeutic use , Pyrimidines/therapeutic use
8.
Journal of Experimental Hematology ; (6): 771-777, 2022.
Article in Chinese | WPRIM | ID: wpr-939687

ABSTRACT

OBJECTIVE@#To investigate the potential inhibitory effect of interference with PD-L1 on B cell lymphoma in mice.@*METHODS@#Three shRNA vectors for mouse CD274 (PD-L1) were constructed and transiently transfected into 293T cells. RT-qPCR was used to validate the interference efficiency of CD274. The shRNA vector that interfere efficiently with CD274 expression was packaged by using lentivirus packaging system to generate shRNA lentivirus, and then transfected into A20 lymphoma cell line. The methyl thiazol terazolium (MTT) assay was used to detect proliferation after 48 h culture of CD274-sh A20 cells. Meanwhile, BALB/c mice were hypodermically infected with CD274-sh A20 cells. Infected mice were observed daily and assessed to visualize tumor by in vivo fluorescence imaging.@*RESULTS@#The proliferation rate of CD274-sh A20 cells in vitro was significantly lower than that of A20 cells (P<0.05). The tumor size detected by in vivo fluorescence imaging showed a significant reduce in tumor bearing mice with CD274-sh compared with other tumor bearing mice. And the weight and size of tumor in CD274-sh group were also significantly reduced compared with other group (P<0.05). Moreover, the survival time of tumor bearing mice in CD274-sh group was longer than that of the PD-L1 high expression group.@*CONCLUSION@#PD-L1 plays an important role in the incidence and the progression of lymphoma, and the shRNA-based PD-L1 knockdown can inhibit cell proliferation of A20 cells and partly suppress tumor growth.


Subject(s)
Animals , Humans , Mice , B7-H1 Antigen/metabolism , Cell Line, Tumor , Lymphoma , Lymphoma, B-Cell , Mice, Inbred BALB C , RNA, Small Interfering/genetics
10.
Article in Spanish | LILACS, CUMED | ID: biblio-1408410

ABSTRACT

Introducción: El Linfoma de células grandes B CD5 positivo (LDCGB CD5+) constituye una patología rara y agresiva con pobre respuesta a la quimioinmunoterapia. Objetivo: Describir un caso con diagnóstico de LDCGB CD5+ con recurrencia inusual prostática. Caso clínico: Paciente varón de 61 años con sintomatología de dolor abdominal y síntomas B. Los estudios de imagen mostraron adenopatías mediastinales y retroperitoneales. El informe patológico fue compatible LDCGB CD5+, recibiendo terapia de primera línea con R-CHOP logrando remisión completa, con recaída precoz prostática confirmada por inmunohistoquímica. Posteriormente, inicia terapia de rescate con R-ICE, con pobre respuesta y deterioro del estado funcional. Conclusiones: El LDCGB CD5 + representa una patología infrecuente y agresiva, siendo la recaída en próstata un evento muy inusual, es por ello que los exámenes clínicos exhaustivos y anatomo-patológico son esenciales para un diagnóstico certero. A la fecha, la respuesta a terapias estándar o de mayor intensidad son desalentadoras, por lo que es necesario un mayor número de estudios a futuro(AU)


Introduction: CD5 positive Large B-cell Lymphoma (CD5 + DLBCL) constitutes a rare and aggressive pathology with poor response to chemoimmunotherapy. Objective: To describe a case with a diagnosis of CD5 + DLBCL with an unusual recurrence in the prostate. Clinical case: A 61-year-old male presented abdominal pain and B symptoms. Imaging studies showed mediastinal and retroperitoneal lymphadenopathy. The pathology informed a CD5+ DLBCL diagnosis, receiving first-line R-CHOP treatment and achieving complete remission, with prostatic early relapse confirmed by immunohistochemistry. Therefore, he received R-ICE as rescue treatment with poor response and performance status decline. Conclusions: CD5 + LDCGB represents a rare and aggressive disease, being the prostate relapse a very unusual event, in which the exhaustive clinical and pathological workup is essential for an accurate diagnosis. To date, the response to standard or higher-intensity therapies is disappointing, so more studies are needed in the future(AU)


Subject(s)
Humans , Male , Middle Aged , Prostate , Immunohistochemistry , Abdominal Pain , Lymphoma, B-Cell , Search and Rescue , Functional Status
11.
Rev. Asoc. Odontol. Argent ; 109(2): 100-106, ago. 2021. ilus
Article in Spanish | LILACS | ID: biblio-1348405

ABSTRACT

Objetivo: Presentar un caso clínico de Linfoma de Burkitt esporádico en cavidad bucal como manifestación inicial en un paciente adulto joven, tratado en el Hospital Interzonal General de Agudos "General José de San Martín" de La Plata. Caso clínico: Un paciente masculino de 20 años de edad se presenta con una lesión tumoral localizada en sector posterior de reborde mandibular, pérdida espontánea de piezas dentarias y parestesia del nervio dentario inferior. Acompañado de un aumento de volumen testicular, compromiso intestinal y poliadenopatías. El cuadro morfológico y de inmuno-marcación confirma un Linfoma de Células B "agresivo". El paciente fue tratado con esquema intensivo de 6 bloques de quimioterapia y terapia intratecal. No se observaron señales de recurrencia durante el período de seguimiento de 12 meses. Las manifestaciones bucales iniciales del Linfoma de Burkitt deben considerarse en el diagnóstico diferencial de las enfermedades bucales benignas. Debido a su naturaleza agresiva, el reconocimiento temprano y rápido de este linfoma es esencial para la administración oportuna de la terapia adecuada y mejora el pronóstico del paciente (AU)


Aim: To present a case of sporadic Burkitt's lymphoma with oral initial manifestatios in a young adult patient, who received treatment at the Hospital Interzonal General de Agudos "General José de San Martín", La Plata. Clinical case: A 20-year-old male patient presents with a tumor lesion located in the posterior area of the mandibular ridge, spontaneous loss of teeth and paresthesia of the inferior dental nerve, increase in testicular volume, intestinal compromise and polyadenopathy. The morphological and immunostaining conditions confirm an "aggressive" B-Cell Lymphoma. The patient received an intensive scheme of 6 blocks of chemotherapy and intrathecal therapy. No signs of recurrence were observed during the 12-month follow-up period. Oral manifestations of Burkitt´s lymphoma in the initial stages should be considered in the differential diagnosis of benign oral diseases. Due to its aggressive nature, early and rapid recognition of these this lymphoma is essential for the timely administration of adequate therapy and for a patient's better prognosis (AU)


Subject(s)
Humans , Male , Adult , Mouth Neoplasms , Burkitt Lymphoma , Argentina , Prognosis , Recurrence , Signs and Symptoms , Lymphoma, B-Cell , Dental Service, Hospital , Early Diagnosis , Diagnosis, Differential , Drug Therapy
12.
Arch. argent. pediatr ; 119(3): e242-e246, Junio 2021. tab, ilus
Article in Spanish | LILACS, BINACIS | ID: biblio-1248200

ABSTRACT

La leucemia linfoblástica aguda (LLA) es la patología oncológica más frecuente en pediatría, y corresponde al 23% de las neoplasias en menores de 15 años. Alrededor del 20% de los pacientes con LLA presentan recaídas, en la mayoría de los casos, en la médula ósea. Las recaídas extramedulares son inusuales y las dos localizaciones más frecuentes son el sistema nervioso central (SNC) y los testículos. Cuando las recaídas ocurren en el SNC, suelen manifestarse con un síndrome meníngeo. El síndrome hipotalámico se define como la presencia de hiperfagia, obesidad y/o cambios en el estado de ánimo, y es una forma de presentación clínica inusual de las recaídas en el SNC y debe alertar al pediatra para mantener un alto índice de sospecha.Se describen cuatro casos que se presentaron con síndrome hipotalámico al momento de desarrollar una recaída de LLA en el SNC


Acute lymphoblastic leukemia (ALL) is the most common malignancy in childhood, corresponding to 23% of cancer in children younger than 15 years old. About 20% of ALL cases will relapse, commonly in the bone marrow. Extramedullar relapses are unusual, and the two most frequent locations are CNS and testicles. ALL relapses, when diagnosed in the CNS, frequently present with clinical features of a meningeal syndrome. The hypothalamic syndrome, consisting of hyperphagia, obesity and / or behavior disturbances, corresponds to an unusual presentation of relapses in this location and should alert pediatricians to suspect it.We describe 4 ALL cases of hypothalamic syndrome at the time of CNS relapse


Subject(s)
Humans , Male , Female , Child, Preschool , Child , Lymphoma, B-Cell , Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Recurrence , Fatal Outcome , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Hypothalamic Diseases/diagnosis
13.
Journal of Experimental Hematology ; (6): 1510-1516, 2021.
Article in Chinese | WPRIM | ID: wpr-922287

ABSTRACT

OBJECTIVE@#To explore the role of follicular helper T cell (Tfh)/ follicular regulatory T cell (Tfr) imbalance in B-cell lymphoma (BCL).@*METHODS@#Sixteen BCL patients who were admitted to the Department of Hematology of The First People's Hospital of Yichang and 20 healthy people from December 2019 to November 2020 were enrolled and respectively divided into observation group and control group. The levels of Tfh and Tfr in peripheral blood were detected by flow cytometry. The changes of Tfh, Tfr, and Tfh/Tfr ratio were compared and the relationship between Tfh/Tfr ratio and efficacy, prognosis was analyzed.@*RESULTS@#Compared with the healthy controls, Tfh and Tfh/Tfr ratio in peripheral blood of the BCL patients increased (P<0.05, P<0.01), while levels of Tfr was decreased (P<0.01). After chemotherapy, Tfh and Tfh/Tfr ratio in peripheral blood of the BCL patients decreased significantly than before chemotherapy (P<0.01), but Tfr was no significant difference. Multivariate analysis showed that Tfh and Tfh/Tfr ratio were positively correlated with international prognostic index (IPI) score and Ann Arbor stage (r=0.626, 0.564, 0.573, 0.608, respectively), while Tfr negatively (r=-0.504, -0.542, respectively). According to the average value of Tfh/Tfr ratio at initial diagnosis, BCL patients were divided into Tfh/Tfr high ratio group and low ratio group. It was found that the complete remission (CR) rate, overall response rate (ORR), and survival time in the high ratio group were significantly lower than the low ratio group (P<0.01).@*CONCLUSION@#There is an imbalance of Tfh/Tfr ratio in peripheral blood of the BCL patients, and those with a high Tfh/Tfr ratio have lower CR, ORR and shorter survival time.


Subject(s)
Humans , Flow Cytometry , Lymphoma, B-Cell , T Follicular Helper Cells , T-Lymphocytes, Helper-Inducer , T-Lymphocytes, Regulatory
14.
Journal of Experimental Hematology ; (6): 1485-1492, 2021.
Article in Chinese | WPRIM | ID: wpr-922283

ABSTRACT

OBJECTIVE@#To explore the regulatory effect of TRIP13 on the proliferation and apoptosis of B-cell lymphoma cells and its possible molecular mechanism by knocking down/overexpressing TRIP13 on the cell lines Granta-519 and JVM-2.@*METHODS@#Lentiviral transfection technology was used to construct Granta-519 and JVM-2 cells with knocked down or overexpressed TRIP13 and their control cells. The efficiency of transfection was determined by fluorescence microscopy. The efficiency of knockdown and overexpression was evaluated by real-time quantitative PCR and Western blot. The proliferation was detected by CCK-8 assay. The apoptosis was detected by the Annexin V-APC single staining. The cell cycle was detected by the PI staining. The expression levels of P53, MDM4, and BCL-2 were evaluated by Western blot.@*RESULTS@#After TRIP13 was knocked down, the proliferation ability of Granta-519 and JVM-2 cells was significantly reduced, and the apoptosis rate significantly increased. After TRIP13 was overexpressed, the proliferation ability of Granta-519 and JVM-2 cells was significantly enhanced, and the apoptosis was significantly reduced. After TRIP13 was knocked down, Granta-519 cells had obvious G@*CONCLUSION@#TRIP13 promotes the proliferation of B-cell lymphoma cells, inhibits their apoptosis, and affects their proliferation and apoptosis by participating in the regulation of the cell cycle. TRIP13 promotes the expression of BCL-2 proteins and inhibits the expression of MDM4 protein in B-cell lymphoma cells.


Subject(s)
Humans , ATPases Associated with Diverse Cellular Activities/metabolism , Apoptosis , Cell Cycle Proteins , Cell Proliferation , Lymphoma, B-Cell , Proto-Oncogene Proteins
15.
Journal of Experimental Hematology ; (6): 500-507, 2021.
Article in Chinese | WPRIM | ID: wpr-880103

ABSTRACT

OBJECTIVE@#To investigate the effect of autophagy on the drug resistance of different human lymphoma cells.@*METHODS@#Human Burkitt's lymphoma cell Daudi, human B lymphoma cell SUDHL-4, and human mantle cell lymphoma cell JeKo-1 were taken as the research subjects. The expression of Atg5 was inhibited by the treatments of autophagy inhibitors or stable interference via lentivirus infection. The autophagy activity of B lymphoma cell was changed, and the changes of lymphoma cells to the drug resistance of ADR and VCR was observed.@*RESULTS@#JeKo-1 cells showed the strongest resistance to ADR and VCR, followed by SUDHL-4, and Daudi cells showed the weakest resistance to ADR and VCR. At the same time, JeKo-1 cells showed the strongest autophagy activity, followed by SUDHL-4, and Daudi cells showed the weakest autophagy activity. After the treatments of autophagy inhibitors or stable Atg5 interference, the resistance of lymphoma cells to ADR and VCR was significantly weakened, and there was the positive correlation at the drug resistance and the autophagy activity of B lymphoma cell.@*CONCLUSION@#The higher autophagy activity in lymphoma cells, the lower chemotherapy resistance of the lymphoma cells after autophagy was inhibited.


Subject(s)
Adult , Humans , Autophagy , Burkitt Lymphoma , Cell Line, Tumor , Drug Resistance , Lymphoma, B-Cell
16.
Arq. bras. med. vet. zootec. (Online) ; 72(3): 787-793, May-June, 2020. tab
Article in English | LILACS, VETINDEX | ID: biblio-1129177

ABSTRACT

The immunophenotype is regarded as an independent prognostic factor in high-grade lymphomas, seeing that lymphomas of T-cell origin are associated with shorter survival time. Although a number of studies have evaluated the immunophenotypical profile of lymphoma in the USA and Europe, Brazilian research on the matter remains scarce. Exact characterization of the histopathological type is crucial to establish proper treatment and prognosis. This study evaluated the database of immunohistochemistry laboratories that perform immunophenotyping of canine lymphoma in Brazil. A total of 203 cases of multicentric lymphoma were classified according to the WHO classification. Immunophenotyping was able to identify 71.4% lymphomas of B-cell line, 27.1% of T-cell line and 1.5% of non-B cells and non-T cell lines. Diffuse large B-cell lymphoma was the most common with 59.1% of the cases. Among T-cell lymphomas, lymphoblastic was the most common (11.33% of the cases). Even though canine lymphomas tend to be high-grade, indolent lymphomas comprised 11.82% of the cases and T-zone lymphoma was the most prevalent (8.86%). The immunophenotype of multicentric lymphoma in Brazil is similar to those in other parts of the world, which suggests similar etiologic factors to the development of this disease.(AU)


O imunofenótipo é considerado um fator prognóstico independente em linfomas de alto grau, visto que os linfomas de origem de células T estão associados a menor tempo de sobrevida. Apesar de vários estudos terem avaliado o perfil imunofenotípico do linfoma nos EUA e na Europa, a pesquisa brasileira sobre o assunto ainda é escassa. A caracterização exata do tipo histopatológico é crucial para estabelecer o tratamento e o prognóstico adequados. Este estudo avaliou a base de dados de laboratórios de imuno-histoquímica que realizam imunofenotipagem do linfoma canino no Brasil. Um total de 203 casos de linfoma multicêntrico foi classificado de acordo com a classificação da OMS. A imunofenotipagem foi capaz de identificar 71,4% dos linfomas da linhagem de células B, 27,1% da linhagem de células T e 1,5% das linhagens de células não B e não T. O linfoma difuso de grandes células B foi o mais comum em 59,1% dos casos. Entre os linfomas de células T, o linfoblástico foi o mais comum (11, 33% dos casos). Embora os linfomas caninos tendam a ser de alto grau, os linfomas indolentes representaram 11,82% dos casos e o linfoma da zona T foi o mais prevalente (8,86%). O imunofenótipo do linfoma multicêntrico no Brasil é semelhante ao de outras partes do mundo, o que sugere fatores etiológicos semelhantes ao desenvolvimento dessa doença.(AU)


Subject(s)
Animals , Dogs , Immunophenotyping/veterinary , Lymphoma, B-Cell/classification , Lymphoma, T-Cell/classification , Lymphoma, Large B-Cell, Diffuse/classification , Precursor Cell Lymphoblastic Leukemia-Lymphoma/classification , Brazil
17.
Autops. Case Rep ; 10(2): e2020170, Apr.-June 2020. tab, graf
Article in English | LILACS | ID: biblio-1131812

ABSTRACT

Histiocytic sarcoma (HS) is a rare hematolymphoid malignant neoplasm with an aggressive clinical course. It can arise de novo or from low-grade B-cell lymphoma. We describe the case of a 16-year-old boy referred to our hospital with generalized lymphadenopathy, weight loss, and decreased appetite for one month. The patient died undiagnosed on the 7th day of hospitalization. Lymph node and bone marrow biopsies were performed one day before the patient died. The lymph node biopsy revealed an architectural effacement with a diffuse proliferation of large pleomorphic neoplastic cells containing large, multilobulated nuclei, coarse vesicular chromatin, prominent nucleoli, and a moderate amount of eosinophilic cytoplasm. The bone marrow aspiration smears and biopsy also showed evidence of infiltration by these above-mentioned cells. Based on the morphology, along with the exclusion of many differential diagnoses by an extensive panel of immunohistochemical markers, a diagnosis of HS was made. This case report aims at evaluating all the clinical and immunophenotypic features of a case of HS with multifocal presentation and an aggressive clinical course in order to give a correct and definite diagnosis at the proper time.


Subject(s)
Humans , Male , Adolescent , Histiocytic Sarcoma/pathology , Autopsy , Immunophenotyping , Lymphoma, B-Cell , Fatal Outcome , Diagnosis, Differential , Lymphadenopathy
18.
Hematol., Transfus. Cell Ther. (Impr.) ; 42(2): 103-110, Apr.-June 2020. ilus
Article in English | LILACS | ID: biblio-1134022

ABSTRACT

ABSTRACT: The novel Coronavirus (CoVid-19) outbreak is now consider a world pandemic, affecting more than 1,300,000 people worldwide. Cancer patients are in risk for severe disease, including a higher risk of intensive care unit (ICU) admission, need for invasive ventilation or death. Management of patients with lymphoid malignancies can be challenging during the outbreak, due to need of multiple hospital visits and admissions, immunosuppression and need for chemotherapy, radiotherapy and stem cell transplantation. In this article, we will focus on the practical management of patients with lymphoid malignancies during the COVID-19 pandemic, focusing on minimizing the risk for patients.


Subject(s)
Leukemia, Lymphoid , Coronavirus , COVID-19 , Lymphoma , Hodgkin Disease , Leukemia, Lymphocytic, Chronic, B-Cell , Lymphoma, B-Cell , Lymphoma, T-Cell, Peripheral , Lymphoma, Mantle-Cell
20.
Metro cienc ; 28(1): 20-24, 2020 enero -marzo. ilus
Article in Spanish | LILACS | ID: biblio-1128410

ABSTRACT

RESUMEN: El absceso esplénico es una patología poco frecuente; su incidencia es baja (0,2 a 0,7%)1,2; por tanto, es importante individualizar el tratamiento, buscar su causa y ofrecer al paciente el mejor manejo. Hasta hace algunos años, un absceso esplénico se lo trataba siempre mediante esplenectomía; sin embargo, actualmente, debido a la importante función inmunitaria del bazo, su extirpación quirúrgica es la última alternativa. Inicialmente, se debe intentar tratamiento médico con antibióticos de amplio espectro; luego probablemente se requiera pensar en el drenaje guiado por tomografía y, finalmente, la tercera opción es la esplenectomía. En este artículo presentamos el caso de un paciente con un absceso esplénico grande (aproximadamente 550 ml) del polo superior, secundario a un linfoma esplénico abscedado que fistulizó hacia el fondo gástrico. A propósito de este paciente, revisamos la literatura médica y realizamos algunas recomendaciones para el manejo de esta patología.


ABSTRACT: Splenic abscess is a rare condition with a low incidence (0,2 to 0,7%). It is important to individualize treatment, seek its source and offer the patient the best management. Until a few years ago a splenic abscess was always treated with splenectomy. Nowadays, due to the important immune function of the spleen surgical removal is the last alternative. Initially medical treatment with broad spectrum antibiotics should be attempted. The next step is usually tomography-guided drainage. The last step used if other methods fail is splenectomy. In this article we present a case of a patient with a large splenic abscess (550 ml approximately) from the upper pole secondary to B cell lymphoma that fistulized towards the gastric fundus. We reviewed the current medical literature regarding this pathology and the current treatment algorithm.Keywords: splenic abscess, B cell lymphoma, gastrosplenic fistula.


Subject(s)
Humans , Male , Middle Aged , Splenectomy , Lymphoma, B-Cell , Fistula , Spleen , Therapeutics , Abscess
SELECTION OF CITATIONS
SEARCH DETAIL